Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment

被引：34

作者：

Cramer, Sarah D. ^{[1
,2
,3
]}

Aplan, Peter D. ^{[4
]}

Durum, Scott K. ^{[1
]}

机构：

[1] NCI, Cytokines & Immun Sect, Canc & Inflammat Program, NIH, Bldg 560,Room 31-71, Frederick, MD 21702 USA

[2] NIH, Comparat Biomed Scientist Training Program, Bldg 10, Bethesda, MD 20892 USA

[3] Univ Maryland, Dept Vet Med, College Pk, MD 20742 USA

[4] NCI, Leukemia Biol Sect, Genet Branch, NIH, Bethesda, MD 20892 USA

来源：

BLOOD | 2016年 / 128卷 / 04期

基金：

美国国家卫生研究院;

关键词：

ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL PRECURSOR; CHILDRENS ONCOLOGY GROUP; THYMIC STROMAL LYMPHOPOIETIN; MURINE XENOGRAFT MODELS; OF-FUNCTION MUTATIONS; T-ALL; CYTOTOXIC ACTIVITY; CRLF2; EXPRESSION; MTOR INHIBITORS;

D O I：

10.1182/blood-2016-03-679209

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Increased understanding of pediatric acute lymphoblastic leukemia (ALL) pathobiology has led to dramatic improvements in patient survival. However, there is still a needto developtargeted therapies toenable reduced chemotherapy intensity and to treat relapsed patients. The interleukin-7 receptor alpha ( IL-7R alpha) signaling pathways areprime therapeutic targetsbecause these pathways harbor genetic aberrations in both T-cell ALL and B-cell precursor ALL. Therapeutic targeting of the IL-7R alpha signaling pathways may lead to improved outcomes in a subset of patients.

引用

页码：473 / 478

页数：6

共 94 条

[1] Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts [J].

Agnusdei, V. ;

Minuzzo, S. ;

Frasson, C. ;

Grassi, A. ;

Axelrod, F. ;

Satyal, S. ;

Gurney, A. ;

Hoey, T. ;

Seganfreddo, E. ;

Basso, G. ;

Valtorta, S. ;

Moresco, R. M. ;

Amadori, A. ;

Indraccolo, S. .

LEUKEMIA, 2014, 28 (02) :278-288

[2] JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study [J].

Asnafi, Vahid ;

Le Noir, Sandrine ;

Lhermitte, Ludovic ;

Gardin, Claude ;

Legrand, Faezeh ;

Vallantin, Xavier ;

Malfuson, Jean-Valere ;

Ifrah, Norbert ;

Dombret, Herve ;

Macintyre, Elizabeth .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (01) :179-179

[3] High Accuracy Mutation Detection in Leukemia on a Selected Panel of Cancer Genes [J].

Atak, Zeynep Kalender ;

De Keersmaecker, Kim ;

Gianfelici, Valentina ;

Geerdens, Ellen ;

Vandepoel, Roel ;

Pauwels, Daphnie ;

Porcu, Michael ;

Lahortiga, Idoya ;

Brys, Vanessa ;

Dirks, Willy G. ;

Quentmeier, Hilmar ;

Cloos, Jacqueline ;

Cuppens, Harry ;

Uyttebroeck, Anne ;

Vandenberghe, Peter ;

Cools, Jan ;

Aerts, Stein .

PLOS ONE, 2012, 7 (06)

[4] Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia [J].

Bains, T. ;

Heinrich, M. C. ;

Loriaux, M. M. ;

Beadling, C. ;

Nelson, D. ;

Warrick, A. ;

Neff, T. L. ;

Tyner, J. W. ;

Dunlap, J. ;

Corless, C. L. ;

Fan, G. .

LEUKEMIA, 2012, 26 (09) :2144-2146

[5] The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse [J].

Bandapalli, Obul R. ;

Schuessele, Stephanie ;

Kunz, Joachim B. ;

Rausch, Tobias ;

Stutz, Adrian M. ;

Tal, Noa ;

Geron, Ifat ;

Gershman, Nava ;

Izraeli, Shai ;

Eilers, Juliane ;

Vaezipour, Nina ;

Kirschner-Schwabe, Renate ;

Hof, Jana ;

von Stackelberg, Arend ;

Schrappe, Martin ;

Stanulla, Martin ;

Zimmermann, Martin ;

Koehler, Rolf ;

Avigad, Smadar ;

Handgretinger, Rupert ;

Frismantas, Viktoras ;

Bourquin, Jean Pierre ;

Bornhauser, Beat ;

Korbel, Jan O. ;

Muckenthaler, Martina U. ;

Kulozik, Andreas E. .

HAEMATOLOGICA, 2014, 99 (10) :E188-E192

[6] Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells [J].

Barata, JT ;

Silva, A ;

Brandao, JG ;

Nadler, LM ;

Cardoso, AA ;

Boussiotis, VA .

JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (05) :659-669

[7] Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27kip1 [J].

Barata, JT ;

Cardoso, AA ;

Nadler, LM ;

Boussiotis, VA .

BLOOD, 2001, 98 (05) :1524-1531

[8] Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome [J].

Bercovich, Dani ;

Ganmore, Ithamar ;

Scott, Linda M. ;

Wainreb, Gilad ;

Birger, Yehudit ;

Elimelech, Arava ;

Chen, Shochat ;

Cazzaniga, Giovanni ;

Biondi, Andrea ;

Basso, Giuseppe ;

Cario, Gunnar ;

Schrappe, Martin ;

Stanulla, Martin ;

Strehl, Sabine ;

Haas, Oskar A. ;

Mann, Georg ;

Binder, Vera ;

Borkhardt, Arndt ;

Kempski, Helena ;

Trka, Jan ;

Bielorei, Bella ;

Avigad, Smadar ;

Stark, Batia ;

Smith, Owen ;

Dastugue, Nicole ;

Bourquin, Jean-Pierre ;

Ben Tal, Nir ;

Green, Anthony R. ;

Izraeli, Shai .

LANCET, 2008, 372 (9648) :1484-1492

[9] Expression analysis and specific blockade of the receptor for human thymic stromal lymphopoietin (TSLP) by novel antibodies to the human TSLPRα receptor chain [J].

Borowski, Andreas ;

Vetter, Tina ;

Kuepper, Michael ;

Wohlmann, Andreas ;

Krause, Sebastian ;

Lorenzen, Thomas ;

Virchow, Johann Christian ;

Luttmann, Werner ;

Friedrich, Karlheinz .

CYTOKINE, 2013, 61 (02) :546-555

[10] Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by Il-7-mediated signalling [J].

Brown, VI ;

Fang, JJ ;

Alcorn, K ;

Barr, R ;

Kim, JM ;

Wasserman, R ;

Grupp, SA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (25) :15113-15118

← 1 2 3 4 5 6 7 8 9 10 →